Sunday, September 4, 2016

BRIEF-Dynavax says PDUFA date for Heplisav-B remains unchanged

* u.s FDA center for biologics evaluation and research

cancelled vrbpac meeting to review biologics license application

for heplisav-b

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)